Skip to content
Screener

Cogent Biosciences, Inc. COGT Operating Lease Liabilities

Operating Lease Liabilities at other companies

Tango Therapeutics logo
Tango TherapeuticsTNGX
$29.96M-12.2%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$26.64M-13.1%
Immunome logo
ImmunomeIMNM
$3.69M-22.6%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$4.21M+192%
Sutro Biopharma logo
Sutro BiopharmaSTRO
$6.03M-55.8%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$33.36M-9.9%

Other financials

Income statement

See full
Operating income-$103.6M-38.3%
Net income-$97.4M-35.2%
EPS (diluted)-$0.53-1.9%

Balance sheet

See full
Cash & equivalents$241.2M+91.4%
Total debt$15.5M-9.4%
Total equity$607.7M+177%
Total assets$903.0M+218%

Cash flow

See full
Operating cash flow-$86.9M-30.6%
CapEx$449.0K-17.9%
Free cash flow-$87.3M-30.2%

Valuation

See full
Market cap$7.14B+366%
Enterprise value$6.92B+372%

Profitability

See full
Operating margin-1,044.3%
Net margin-950.4%
FCF margin-184.7%

Returns & leverage

See full
Return on equity-85.7%+1.7pp
Debt / equity-0.1×
Current ratio15.1×+10.0×

Where this comes from

Reported directly by Cogent Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.

The source filing: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 8:21 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-205170
Line itemMarch 31, 2026December 31, 2025
Operating lease liabilities1,3831,547
Total current liabilities57,98163,953
Convertible senior notes, net223,173222,895
Operating lease liabilities, net of current portion14,09714,355
Other liabilities6233
Total liabilities295,313301,236
Commitments and contingencies (Note 7)
Stockholders’ equity:

Item 1. Financial Statements (Unaudited)

FAQ

What is Cogent Biosciences, Inc.'s operating lease liabilities?
Cogent Biosciences, Inc. (COGT) reported operating lease liabilities of $14.1M in Q1 2026.
How has Cogent Biosciences, Inc.'s operating lease liabilities changed year-over-year?
Cogent Biosciences, Inc.'s operating lease liabilities decreased by 8.9% year-over-year, from $15.48M to $14.1M.
What is the long-term trend for Cogent Biosciences, Inc.'s operating lease liabilities?
Over 5 years (2020 to 2025), Cogent Biosciences, Inc.'s operating lease liabilities has grown at a 35.4% compound annual growth rate (CAGR), from $3.16M to $14.36M.
What does operating lease liabilities mean?
Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.

Ask your AI about Cogent Biosciences, Inc.'s operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude